Nanovaccines against Viral Infection
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 60
Special Issue Editors
Interests: porcine circovirus (PCV); pseudorabies virus (PRV); porcine epidemic diarrhea virus (PEDV); porcine deltacoronavirus (PDCoV); SeACoV (swine enteric alphacoronavirus)/SADS-CoV (swine acute diarrhea syndrome coronavirus); other emerging or re-emerging viruses; vaccine; antibody
Special Issues, Collections and Topics in MDPI journals
Interests: molecular epidemiology and investigating the pathogenic mechanisms of animal viruses; novel vaccines; nanobodies; Newcastle disease; avian influenza; canine parvovirus; feline panleukopenia; Brucella
Special Issue Information
Dear Colleagues,
Viral diseases, especially life-threatening pathogens such as SARS-CoV-2, smallpox, influenza and ASFV, have substantial implications on public and animal health, and subsequently global economies. Vaccination is a crucial approach to combat existing and emerging viruses. However, optimizing the potency, improving the quality and enhancing the durability of immune responses remain challenges. Nanoparticles could be an effective method for developing novel vaccinations. Nanovaccines trigger a robust immune response, allowing for diseases to be controlled or killed and spread to a minimum. They are designed such that the antigen can be on the exterior or inside the nanoparticles, allowing for efficient distribution. As a result, an encapsulated antigen is more difficult to break down, and the release is more tightly regulated at the target region. Controlled antigen release prevents an exaggerated reaction and eliminates the need for booster doses. In this Special Issue, we aim to present nanoantibodies and nanovaccines against viral infection. An emphasis will be placed on the reports focused on designing and evaluating nanoparticles, nano-based adjuvants, nanoantibodies, etc. Original research articles and reviews are welcome.
Prof. Dr. Linzhu Ren
Dr. Jing Qian
Dr. Fuxian Zhang
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanoparticle
- nanoantibody
- nanovaccine
- peptide-based nanovaccine
- adjuvant and nanoadjuvant
- antigen
- nanotechnology in virus research
